ModifiedPremera BluecrossPolicy 2.01.533

Upper gastrointestinal (UGI) endoscopy (EGD) coverage/medical necessity

Policy defines medical necessity criteria for upper gastrointestinal endoscopy (EGD/UGI) for individuals aged 19 and older, listing malignant indications, alarm symptoms, follow-up of known non-malignant conditions, GERD/dyspepsia criteria, other indications, and not medically necessary situations; includes coding, definitions, evidence and guideline references.

Policy Summary

PayerPremera Bluecross

PolicyUpper gastrointestinal (UGI) endoscopy (EGD) coverage/medical necessity

Policy CodePolicy 2.01.533

Change TypeModified coverage criteria and clarifications

Effective DateFeb 1, 2026

Next Review Date

Key ActionDocument malignant indications, alarm symptoms, high-risk non-malignant conditions, or GERD/dyspepsia criteria (>=3 months and after 8-week PPI trial or return after discontinuation) to support medical necessity for members aged 19 and older.

SourceLink

POLICY UPDATE CHANGES

Policy has been updated; references to related medical policies and cross-links updated and policy marked as updated.

Policy statement updated to require GERD/dyspepsia symptoms persist despite 8 weeks of continuous daily PPI therapy or to allow UGI when symptoms return after PPI discontinuation (06/01/22).

Preoperative UGI prior to bariatric surgery changed to medically necessary (01/01/23).

UGI considered medically necessary for endoscopic ultrasound guided fine needle aspiration/biopsy(s) of adjacent organs or structures (10/01/23).

BE surveillance interval for low grade dysplasia updated: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter (03/01/24).

Clarified UGI medically necessary for family history of gastric/esophageal/duodenal cancer in a first degree relative and broadened prior adenomatous/sessile polyps to include gastric, duodenal, and esophagus (05/01/24; 09/01/25).

UGI considered not medically necessary for confirming helicobacter pylori eradication (09/01/25).

Modified criterion: UGI may be considered medically necessary for individuals with newly diagnosed (within one year) pernicious anemia (02/01/26).

Header added to indicate site of service review does not apply to IHS facilities (06/01/26).

Coverage Summary

Policy defines medical necessity criteria for upper gastrointestinal endoscopy (EGD/UGI) for individuals aged 19 and older, listing covered indications including malignant indications (e.g., Barrett esophagus, dysplasia, esophageal and gastric cancer, familial syndromes, prior adenomatous/sessile polyps, family history of UGI cancer), alarm symptoms (e.g., iron deficiency anemia, GI bleeding, dysphagia, persistent vomiting, unintentional weight loss ≥ 3 kg), follow-up of known non-malignant conditions (e.g., varices, eosinophilic or erosive esophagitis, treatment of bleeding ulcers with therapeutic endoscopy, ulcer follow-up every 2 months until healed), GERD/dyspepsia criteria (symptoms ≥ 3 months and persist despite 8 weeks continuous daily PPI therapy or evaluation when symptoms return after PPI discontinuation), and other indications (e.g., preoperative evaluation for bariatric surgery, endoscopic ultrasound-guided FNA/FNB, screening for Barrett in selected males, assessment for small-bowel disease/IBD, newly diagnosed pernicious anemia within 1 year).

The policy also lists situations considered not medically necessary (e.g., routine screening without clinical indication; surveillance of healed benign disease or gastric intestinal metaplasia; confirming H. pylori eradication) and includes coding highlights with specified CPT codes to report for EGD (e.g., 43235, 43238, 43239, 43242). Key recent changes and cross-reference updates are noted in the policy header/history and the site-of-service medical necessity criteria exclusion for IHS facilities is specified in the header.

Key thresholds / quick facts

Applicable patient age19+ years

GERD symptom duration for endoscopy>= 3 months

PPI trial duration8 weeks continuous daily PPI therapy

Unintentional weight loss threshold>= 3 kg (approx. 6.6 lbs.) since symptoms started

Barrett surveillance - no dysplasiaRepeat one time within 12 months after initial biopsy; then every 3 years if unchanged

Barrett surveillance - low-grade dysplasiaRepeat at 6 months; then at 12 months and annually thereafter

Barrett surveillance - high-grade dysplasiaRepeat every 3 months after initial biopsy for 1 year, then annually thereafter

Ulcer follow-up intervalEvery 2 months until healed

Pernicious anemia timeframeNewly diagnosed within one year

Screening age/criteria for Barrett in males>= 50 years with >=5 years GERD symptoms plus one or more risk factors (elevated BMI, excess abdominal fat, hiatal hernia, night-time reflux symptoms, tobacco use)

Medical-Necessity Criteria

Malignant indications

Upper gastrointestinal (UGI) endoscopy may be considered medically necessary for any of the following malignant indications:

Barrett esophagus (metaplastic columnar or glandular epithelium) (see surveillance criteria below)

Dysplasia (esophageal or gastric)

Esophageal cancer

Gastric cancer

Familial adenomatous polyposis (FAP)

Head/neck cancer with concern for UGI involvement

Not Medically Necessary / Exclusions

Not medically necessary / Exclusions

Upper gastrointestinal (UGI) endoscopy is considered not medically necessary when criteria are not met for any documented clinical indications or in the following situations:

UGI evaluation of chronic, non-progressive, atypical symptoms considered functional in origin (except rare one-time exam to rule out organic disease when unresponsive to therapy)
Uncomplicated heartburn that responds to conservative medical management
Evaluation when endoscopy results will not alter management
Asymptomatic x-ray findings: deformed duodenal bulb that is asymptomatic or has responded to ulcer therapy

Surveillance — Barrett's Esophagus & Related Follow-up

Surveillance guidance across the policy: esophageal varices treated with banding or sclerotherapy require repeat UGI until eradication is complete, then surveillance 1–3 months after eradication and thereafter every 6–12 months to monitor recurrence; gastric/peptic/esophageal ulcers require follow-up endoscopy every 2 months until healed; and Barrett esophagus surveillance intervals were updated to specify low-grade dysplasia surveillance (repeat at 6 months, then at 12 months and annually thereafter) while prior criteria specifying other grades of dysplasia were removed.

Coding

Covered CPTCPTCovered

43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure).
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures).
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple.
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis).

Informational / historical CPT changes mentionedCPT

43233	UGI-related CPT code referenced as added/removed in historical notes
43234	Informational code referenced in history
43236	CPT code removed (clarified 2018 history)
43237	Informational CPT code removed in 2015
43240	Informational CPT code removed in 2015
43241	Informational CPT code removed in 2015
43243	Informational CPT code removed in 2015
43252	CPT code removed from policy 09/05/13 as pertains to another policy
43253	Added as new CPT code in 2014 per history
43254	Added as new CPT code in 2014 per history

1–10 of 15

1/2

Note: the policy header clarifies that the site-of-service medical necessity review does not apply to Indian Health Services (IHS) facilities; providers must report the appropriate CPT code for the procedure performed per the policy coding guidance (examples include 43235, 43238, 43239, 43242).

Provider Actions & Documentation Requirements

Documentation Required

Clinical notes required

Clinical notes must document malignant indications, alarm symptoms, or high-risk non-malignant conditions, or document GERD/dyspepsia criteria (symptoms ≥3 months and either persist despite an 8‑week continuous daily PPI trial or recur after PPI discontinuation) to support medical necessity for individuals aged 19 and older.

Document malignant indications (e.g., Barrett esophagus, dysplasia, esophageal or gastric cancer, FAP, prior adenomatous/sessile polyps, family history of UGI cancer, CDH1 mutation, tylosis)
Document alarm symptoms (e.g., iron deficiency anemia, GI bleeding, epigastric mass, persistent vomiting, dysphagia, unintentional weight loss ≥3 kg)
Document high‑risk non‑malignant conditions needing follow‑up (e.g., portal hypertension/cirrhosis with varices, eosinophilic esophagitis, erosive esophagitis)
For GERD/dyspepsia: symptoms present ≥3 months AND persist despite 8 weeks continuous daily PPI therapy, or evaluation when symptoms return after PPI discontinuation
Applicable patient age: 19+ years

Background & Evidence

Background: Esophagogastroduodenoscopy (EGD/UGI) is a diagnostic and therapeutic endoscopic examination of the esophagus, stomach, and first portion of the small intestine (duodenum) using a flexible endoscope inserted transorally; it is used to evaluate causes of severe heartburn, dysphagia, persistent vomiting, and GI bleeding and to perform interventions such as biopsy, polyp removal, treatment of bleeding lesions, and foreign-body removal. This policy applies to individuals aged 19 and older, and the site-of-service medical necessity criteria do not apply to Indian Health Services (IHS) facilities as noted in the policy header.

Definitions

Key evidence (brief.evidence)

ACP best practiceEndoscopy indicated with heartburn plus alarm symptoms; trial of 4-8 weeks twice-daily PPI for persistent GERD before endoscopy in many cases.

ACG guidanceRecommend 8-week PPI trial for classic GERD without alarm symptoms; endoscopy after failed 8-week PPI or return after discontinuation; surveillance intervals for Barrett per guidance.

Referenced guideline/literatureMultiple ASGE/AGA/ACG guidelines and peer-reviewed studies cited (references 34-51 and others).

Medicare Determinations

Name	Number	Effective Date / Type
Endoscopy
100.2
National Coverage Determination: 'Endoscopic procedures are covered when reasonable and necessary for the individual patient'
Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic)
L35350
LCD revised 2019-10-17

Revision History

06/10/13policy_created

New policy created (effective Oct 1, 2013); initial history entries and early CPT code additions/changes recorded.

06/01/21clarification

Added medically necessary statement for follow-up of known eosinophilic esophagitis and clarified two-month course of therapy for erosive esophagitis follow-up.

06/01/22material_change

PPI therapy requirement updated: GERD/dyspepsia symptoms must persist despite 8 weeks of continuous daily PPI therapy or UGI may be performed when symptoms return after PPI discontinuation (effective 06/01/22).

Policy Summary

PayerPremera Bluecross

PolicyUpper gastrointestinal (UGI) endoscopy (EGD) coverage/medical necessity

Policy CodePolicy 2.01.533

Change TypeModified coverage criteria and clarifications

Effective DateFeb 1, 2026

Next Review Date

SourceLink

On This Page

Alarm symptoms

Upper gastrointestinal (UGI) endoscopy may be considered medically necessary when performed for evaluation of ANY of the following alarm symptoms that may be associated with an UGI source:

Iron deficiency anemia

Bleeding from the rectum or blood in stool (bright red or dark colored) when an UGI source is suspected

Epigastric mass found on examination

Persistent vomiting of unknown cause, including hematemesis (vomiting blood)

Dysphagia (difficulty swallowing)

Unintentional weight loss of 3 kg (approx. 6.6 lbs.) or more since symptoms started

Follow-up of known non-malignant conditions

Upper gastrointestinal (UGI) endoscopy may be considered medically necessary for follow-up or management of known non-malignant conditions:

Anorexia of unknown cause

Evaluation of individuals with suspected portal hypertension or cirrhosis to document or treat esophageal varices (see Cirrhosis for ongoing screening)

Follow-up of known eosinophilic esophagitis

Follow-up of known erosive esophagitis (may need follow-up UGI to evaluate for Barrett after a 2-month course of therapy)

History of gastric surgery

Non-steroidal anti-inflammatory drug (NSAID) use stopped yet symptoms continue

Persistent non-cardiac chest pain

Dysphagia (difficulty swallowing)

Odynophagia (painful swallowing)

Therapeutic banding/sclerotherapy for esophageal varices

Repeat UGI until eradication of varices is complete
Surveillance after eradication: one to 3 months after eradication is completed
Then every 6 to 12 months thereafter to monitor for recurrence

Treatment of bleeding lesions

Treatment of bleeding from lesions such as ulcers using electrocoagulation, heater probe, laser photocoagulation, or injection therapy
Follow-up endoscopy as clinically indicated until hemostasis and healing are confirmed

GERD or dyspepsia

Upper gastrointestinal (UGI) endoscopy may be considered medically necessary for evaluation of gastroesophageal reflux disease (GERD) or dyspepsia when the following are met:

ALL of the following

Symptoms present for at least 3 months
Persist despite 8 weeks of continuous daily proton pump inhibitor (PPI) therapy

ANY of the following

Performed for evaluation of the return of GERD or dyspepsia symptoms after PPI therapy has been discontinued

Other UGI indications

Upper gastrointestinal (UGI) endoscopy may be considered medically necessary for other UGI indications, including surveillance, preoperative evaluation, targeted diagnostic procedures, and selected screening when risk factors are present:

Achalasia

Barrett esophagus surveillance by pathology

High-grade dysplasia: repeat UGI every 3 months after initial biopsy for 1 year, then annually thereafter
Low-grade dysplasia: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter
No dysplasia (metaplasia): repeat UGI one time within 12 months after initial biopsy; then every 3 years if pathology unchanged

Cirrhosis: upon initial diagnosis, one UGI endoscopy to screen for esophageal varices; ongoing screening no more frequently than annually

Crohn disease involving the esophagus, stomach, or duodenum

Ingestion of a caustic agent

Removal of a foreign body that is known or suspected

Gastric/peptic/esophageal ulcer confirmation

Conservative medical management tried and failed to relieve symptoms (e.g., cessation of NSAIDs, trial of appropriate medication)
Conservative medical management is contraindicated

Follow-up UGI for gastric, peptic, or esophageal ulcer every 2 months until healed

Preoperative bariatric evaluation

Performed for preoperative endoscopic evaluation prior to bariatric surgery
If the member's contract excludes bariatric surgery, UGI is not covered unless another medical necessity criterion is met

Endoscopic ultrasound guided FNA/FNB

Performed for endoscopic ultrasound guided fine needle aspiration/biopsy(s) of adjacent organs or structures (e.g., esophagus, stomach, duodenum, pancreas, liver)

Individuals planned for organ transplantation when presence of upper GI pathology might modify management

Individuals with newly diagnosed (within one year) pernicious anemia

Post cardiac ablation for treatment of arrhythmias

Screening for Barrett in male individuals

Age 50 years or older
≥5 years of GERD symptoms
One or more risk factors: elevated BMI, excess abdominal fat, hiatal hernia, night-time reflux symptoms, or tobacco use

Assessment of diarrhea when small-bowel disease is suspected (e.g., celiac disease or inflammatory bowel disease)

Small bowel disease / inflammatory bowel disease / celiac evaluation when indicated to assess etiology of symptoms or guide management

Documentation Required

Barrett surveillance schedule

Document the pathology findings for Barrett esophagus and follow the specified surveillance intervals based on dysplasia status to justify repeat endoscopies.

High‑grade dysplasia: repeat UGI every 3 months after initial biopsy for 1 year, then annually thereafter
Low‑grade dysplasia: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter
No dysplasia (metaplasia): repeat UGI one time within 12 months after initial biopsy; then every 3 years if pathology unchanged

Documentation Required

Document indication and prior therapies

Document the indication and prior therapies when requesting UGI for GERD/dyspepsia or pernicious anemia: specifically document an 8‑week continuous daily PPI trial that failed (or that symptoms returned after stopping PPI), and when claiming UGI for pernicious anemia document newly diagnosed status within one year.

Evidence of continuous daily PPI therapy for 8 weeks with persistent symptoms, OR documentation that symptoms returned after PPI discontinuation
If claiming UGI for pernicious anemia, document that the diagnosis is newly made within the past year
Applicable to GERD/dyspepsia criteria: symptoms ≥3 months